Needham & Company Reiterates Annexon Biosciences (ANNX) at Buy, Will Seek Changes in cUHRDS and NfL Levels in ANX005 Phase 1/2 trial
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $37.00 price target on Annexon Biosciences (NASDAQ: ANNX), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
